OIS at AAO 2015

ONL Therapeutics

Nov 12, 2015 12:21pm ‐ Nov 12, 2015 12:29pm


ONL is committed to protecting and improving the vision of patients with retinal diseases and conditions, including retinal detachment and dry age-related macular degeneration (AMD). ONL is the first and only company focused on preventing the death of photoreceptors, the leading cause of blindness and a completely unaddressed medical need.


You must be logged in and own this session in order to post comments.